HCPCS J1202: Miglustat, Oral, 65 mg - OpenPayer

Summary & Overview

HCPCS J1202: Miglustat, Oral, 65 mg

HCPCS Level II code J1202 designates Miglustat, oral, 65 mg. This drug-specific code is used for billing the dispensing or administration of an oral specialty medication across outpatient pharmacy and clinic settings. Nationally, utilization of drug-specific HCPCS Level II codes matters for accurate reimbursement, specialty pharmacy operations, and tracking of therapies for rare metabolic conditions. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn what the code represents in clinical and billing terms, where services are typically performed, and which major payers recognize the code. The publication summarizes benchmark considerations, common billing modifiers and service line context, and clinical context relevant to Miglustat use. Missing input fields such as associated taxonomies, ICD-10 diagnoses, related codes, and detailed payer-specific coverage policies are noted as not available in the input. The document is intended for a national audience of coding professionals, revenue cycle managers, and policy analysts seeking a concise reference for HCPCS Level II code J1202.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ1202HCPCS Level IImiglustatoral medicationspecialty pharmacydrug billingoutpatient pharmacyrare disease therapy

Billing Code Overview

HCPCS Level II code J1202 describes Miglustat, oral, 65 mg. This code represents a physician- or pharmacy-dispensed oral pharmaceutical agent used for specific metabolic and rare disease indications. The service type is oral medication administration/dispensing. The typical site of service is outpatient pharmacy or clinic where oral specialty medications are dispensed or administered.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 28-year-old adult with a confirmed diagnosis of Niemann-Pick disease type C (NPC) presents to a specialty metabolic clinic for chronic oral disease-modifying therapy. The patient has been prescribed J1202 (Miglustat, oral, 65 mg) as part of long-term management to slow neurologic progression. The typical clinical workflow includes: initial evaluation by a metabolic or neurology specialist with documentation of diagnosis and baseline neurologic and gastrointestinal status; counseling about dosing, adverse effects (notably gastrointestinal intolerance and weight loss), and fertility/contraception considerations; baseline and periodic laboratory monitoring (complete blood count, liver function tests) and nutritional assessment; pharmacist verification of dose and dispensing instructions; and regular follow-up visits every 3–6 months to assess efficacy and tolerability. Medication may be dispensed in an outpatient specialty pharmacy or hospital outpatient pharmacy, and administration is oral at home; the site of service is typically an outpatient clinic or ambulatory specialty pharmacy pick-up with telehealth follow-up as needed. Payors involved often include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for coverage determinations and prior authorization processes.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	When documentation supports substantially greater work, such as extensive clinical counseling about off-label use or complex dosing adjustments for .

HCPCS J2460: Injection, Oxytetracycline HCl, Up to 50 mg

HCPCS-J0480-BASILIXIMAB-INJECTION-20MG

HCPCS J0480: Basiliximab Injection, 20 mg

HCPCS-J8515-CABERGOLINE-ORAL-025-MG

HCPCS Level II J8515: Cabergoline, Oral, 0.25 mg

HCPCS-J1611-GLUCAGON-HYDROCHLORIDE-INJECTION-FRESENIUS-KABI

HCPCS Level II J1611: Glucagon Hydrochloride Injection (Fresenius Kabi)

HCPCS-J7198-ANTI-INHIBITOR-PER-IU-INJECTABLE-BIOLOGIC

HCPCS Level II J7198: Anti-inhibitor, per i.u.

HCPCS-J7211-FACTOR-VIII-KOVALTRY-RECOMBINANT-INJECTION

HCPCS J7211: Factor VIII (Kovaltry) Injection, Recombinant, per 1 I.U.

HCPCS-J2267-MIRIKIZUMAB-INJECTION-1MG

HCPCS J2267: Injection, mirikizumab-mrkz, 1 mg

HCPCS-J7351-BIMATOPROST-INTRACAMERAL-IMPLANT-1-MCG

HCPCS Level II J7351: Bimatoprost Intracameral Implant, 1 mcg

HCPCS-J0013-ESKETAMINE-NASAL-SPRAY-1MG

HCPCS Level II J0013: Esketamine Nasal Spray, 1 mg

HCPCS-J0589-DAXIBOTULINUMTOXINA-INJECTION-1-UNIT

HCPCS J0589: Injection, daxibotulinumtoxina-lanm, 1 unit

Showing 1–10 of 991

J1202

Taxonomy Code	Specialty	Notes
`207R00000X`	Neurology	Neurologists commonly diagnose and manage Niemann-Pick type C and prescribe disease-modifying therapy.
`2080P0207X`	Clinical Pharmacology	Clinical pharmacologists or specialists in metabolic therapies advise on dosing and interactions for `J1202`.
`363L00000X`	Pediatric Medicine	Pediatricians or pediatric metabolic specialists initiate and monitor therapy in pediatric patients with NPC.
`163WP0800X`	Medical Genetics	Medical geneticists confirm diagnosis and provide genetic counseling related to inherited metabolic diseases.
`251B00000X`	Pharmacy	Specialty pharmacists manage dispensing, prior authorization, and patient education for oral miglustat.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`E75.240`	Niemann-Pick disease type C without behavioral disturbance	Primary indication for miglustat therapy to slow neurologic progression in NPC.
`E75.241`	Niemann-Pick disease type C with behavioral disturbance	NPC patients with behavioral manifestations may receive miglustat as part of management.
`E75.242`	Niemann-Pick disease type C with motor dysfunction	Motor symptoms are a common target of therapy monitoring when on `J1202`.
`E75.243`	Niemann-Pick disease type C with other neurologic manifestation	Includes seizures, ataxia, and other neurologic signs monitored during therapy.
`E70.2`	Disorders of aromatic amino-acid metabolism	Related inherited metabolic disorders sometimes evaluated by the same specialist teams; considered in differential diagnosis.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Commonly billed for follow-up visits to monitor response and tolerability after initiating `J1202`.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, typically 25 minutes	Used for more complex follow-up visits involving extensive counseling, medication management, or prior authorization tasks.
`99406`	Smoking and tobacco use cessation counseling, intermediate, greater than 3 minutes up to 10 minutes	Occasionally used if smoking cessation counseling is provided as part of comprehensive care (behavioral counseling that may affect drug metabolism or overall health).
`36415`	Collection of venous blood by venipuncture	Used for laboratory monitoring (CBC, liver function tests) required during therapy with `J1202`.
`81002`	Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, pH, protein, etc.; non-automated, without microscopy	Used for baseline or follow-up assessments when clinical care protocols include urinalysis.
`99070`	Supplies and materials provided by the physician over and above those usually included with the office visit	Used when additional supplies (e.g., educational materials, special packaging) are provided during medication dispensing.

OpenPayer